Immunic Therapeutics

#Clinical trial #Immunic Therapeutics #MS #Multiple sclerosis

Immunic appoints Erik Lundgren as CEO 

Biotechnology company Immunic Therapeutics has appointed Erik Lundgren as Chief Executive Officer.  Immunic says Lundgren will lead the company as it advances vidofludimus calcium through late-stage clinical development. Vidofludimus calcium has shown therapeutic activity in Phase II clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases.  Lundgren recently served… Read More

#News

Immunotherapy
#Autoimmune disease #Immunic Therapeutics #Immunology #MS #Neurodegenerative disorders #Neurology

Moving beyond managing autoimmune diseases to progression

What if we’re finally moving beyond managing autoimmune diseases and toward slowing their progression? That’s the promise behind Immunic Therapeutics' recent long-term data on vidofludimus calcium (IMU‑838. Dr Daniel Vitt, CEO of Immunic, discusses these results and insights with DDW’s Megan Thomas. MT: Can you unpack what the sustained neuroprotective… Read More

#Exclusive Content